Research Article
Rapid Dantrolene Administration with Body Temperature Monitoring Is Associated with Decreased Mortality in Japanese Malignant Hyperthermia Events
Table 4
Clinical and biochemical presentations at dantrolene administration.
| | Survivor () | Deceased () | value | | Median | (IQR) | | Median | (IQR) | |
| | Maximum rate of increase in body temperature (°C/15 min) | 0.80 | (0.50-1.00) | 93 | 0.65 | (0.53-1.32) | 8 | 0.81 | | Maximum body temperature (°C) | 39.7 | (38.8-40.9) | 104 | 41.8 | (39.9-43.0) | 10 | 0.0017 | | Maximum PaCO2 (mmHg) | 70.8 | (56.4-89.0) | 82 | 94.8 | (48.7-152.1) | 7 | 0.25 | | Maximum ETCO2 (mmHg) | 75.0 | (65.0-96.5) | 81 | 84.0 | (71.3-113.3) | 4 | 0.45 | | Lowest arterial pH | 7.17 | (7.05-7.23) | 82 | 6.96 | (6.82-7.11) | 8 | 0.0014 | | Lowest arterial base excess | -4.35 | (−8.80-−2.00) | 78 | -14.05 | (−19.9-−11.4) | 8 | < 0.0001 | | Highest creatinine kinase (IU/L) | 3304 | (1259-25766) | 91 | 28064 | (1723-223740) | 8 | 0.12 | | Highest serum myoglobin (ng/mL) | 1181 | (659-1340) | 35 | 24900 | (1340-112000) | 6 | 0.007 | | Highest potassium (mEq/L) | 5.3 | (4.5-6.0) | 71 | 6.2 | (5.0-7.6) | 9 | 0.021 | | Dose of dantrolene (mg/kg) | 1 | (0.75-1.94) | 27 | 0.98 | (0.90-1.45) | 7 | 0.70 | | Temperature at dantrolene administration (°C) | 39.1 | (38.5-40.3) | 43 | 41.6 | (39.9-42.8) | 10 | < 0.001 | | Anesthetic induction to first MH sign (min) | 60.0 | (30-130) | 87 | 90.0 | (15-165) | 10 | 0.85 | | Interval from first MH sign to dantrolene administration (min) | 45.0 | (25.0-75.0) | 43 | 100.0 | (75.0-135.0) | 5 | 0.007 |
|
|
Subjects with missing data were excluded. IQR: interquartile range; PaCO2: arterial partial pressure of carbon dioxide; ETCO2: end-tidal carbon dioxide; MH: malignant hyperthermia.
|
